|
AML with recurrent genetic abnormalities
|
|
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
|
|
AML with inv. (16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
|
|
APL with PML-RARA
|
|
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
|
|
AML with t(6;9)(p23;q34.1);DEK-NUP214
|
|
AML with inv. (3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
|
|
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
|
|
Provisional entity: AML with BCR-ABL1
|
|
AML with mutated NPM1
|
|
AML with biallelic mutations of CEBPA
|
|
Provisional entity: AML with mutated RUNX1
|
|
AML with myelodysplasia-related changes
|
|
Therapy-related myeloid neoplasms
|
|
AML, NOS
|
|
AML with minimal differentiation
|
|
AML without maturation
|
|
AML with maturation
|
|
Acute myelomonocytic leukemia
|
|
Acute monoblastic/monocytic leukemia
|
|
Pure erythroid leukemia
|
|
Acute megakaryoblastic leukemia
|
|
Acute basophilic leukemia
|
|
Acute panmyelosis with myelofibrosis
|
|
Myeloid sarcoma
|
|
Myeloid proliferations related to Down syndrome
|
|
Transient abnormal myelopoiesis (TAM)
|
|
Myeloid leukemia associated with Down syndrome
|
